2022/3/14 The first subject participated in phase II human trial of new drug AD17002-SC for COVID-19.
2021/9/27 A memorandum of Understanding (MOU) with Macter International Limited in Pakistan for the authorization and distribution of the new drug AD17002-SC for COVID-19.
2021/7/6 New drug AD17002-SC for the treatment of COVID-19 was approved by TFDA to perform phase II human clinical trials.
2021/5/10 Apply to TFDA for IND of AD17002-SC for the treatment of phase II human clinical trials in patients with mild COVID-19.
2021/4/27 Apply to TFDA for Clinical Trial (IIT) to use AD17002 for the treatment of asthma caused by rhinovirus.
2020/12/23 The results of animal challenge experiments show that the COVID-19 immunotherapy drug AD17002-SC can significantly reduce the lung inflammation caused by moderate to severe virus infections.
2020/11/23 Cooperated with Taipei Medical University(TMU) to implement the research project "the mechanism of action of AD17002-AI application in asthma and allergic rhinitis."
2020/11/23 The research and development project "nasal spray influenza vaccine (106IDX10023)" was selected as a potential product by TFDA.
2020/10/6 Advagene obtained the technology authorization from National Institutes of Health(NIH), to use influenza virus particle platform to develop SARS-Cov-2 antigen. This antigen technology will be used for the development of the second-generation nasal spray COVID-19 vaccine, which can induce both serum and mucosal antibodies after vaccination. And it provides injection-free vaccination and additional mucosal protection.
2020/7/11 Nasal spray new drug AD17002-AI applied to allergic rhinitis treatment in phase Ib/IIa human trial has been completed. The CSR(clinical study report) will be released in December.
2020/4/27 Application of new drug AD17002-SC to COVID-19 immunotherapy was selected as a capstone project by CDE.
2020/4/8 The first subject participated in cohort 3(high-dose group) of Ib/IIa trial of allergic rhinitis immunotherapy.
2020/3/26 The safety data of cohort 2 of allergic rhinitis immunotherapy trial passed SRT(Safety review team) reviewing and got permission to enter cohort 3.
2020/2/25 The cohort 2 trial of allergic rhinitis immunotherapy has been completed.
2020/2/17 Polysaccharide Conjugation with LTh(αΚ) used as Vaccine obtained US patent.
2019/11/14 The expert committee of SRT(Safety review team) reviewed the safety data of AD17002-AI used in cohort 1(low-dose group) of allergic rhinitis immunotherapy trial and agreed to move on to the next stage of the middle-dose group.
2019/11/18 The phase II clinical trial of LT-Flu nasal Flu vaccine has been published in the Vaccine Journal(https://www.ncbi.nlm.nih.gov/pubmed/31812463)
2019/10 Cohort 1 of the Ib/IIa trial of allergic rhinitis immunotherapy has been finished, including 8 weeks of follow-up inspection in the clinical trial center.
2019/3/26 The first subject participated in cohort 1(low-dose group) of the Ib/IIa trial of allergic rhinitis immunotherapy, which is planned to recruit 16 subjects in this stage.
2018/11/5 Obtained the IND approval from the Food and Drug Administration (TFDA) of the Ministry of Health and Welfare in Taiwan "A randomized, placebo-controlled trial to evaluate the safety, tolerability and potential efficacy of intranasal administration on AD17002 [LTh(αΚ)] aim at subjects with allergic rhinitis caused by house-dust mites. "
2017/12 Complete batch production(GMP) of AD17002-AI used in the project of house-dust mite nasal spray allergy treatment Ib/IIa clinical trial.
2018.12 【Money DJ】